NuScale
SMR
$9.03
+3.08%
NuScale Power Corporation is pioneering small modular reactor (SMR) technology to deliver safe, scalable, and carbon-free nuclear power. As a first-mover in the SMR space, it aims to disrupt traditional nuclear energy with its proprietary NuScale Power Module (NPM) that generates 77 MWe. The stock has been under severe pressure, declining over 72% in the past year, driven by commercialization delays, revenue misses, and waning AI enthusiasm. Recent news highlights a failed commercialization narrative and a significant revenue miss in Q1 2026, making the stock a high-risk turnaround story.…
SMR
NuScale
$9.03
Related headlines
SMR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on NuScale's 12-month outlook, with a consensus price target around $11.74 and implied upside of +30.0% versus the current price.
Average Target
$11.74
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$7 - $12
Analyst target range
NuScale is covered by 5 analysts, with a consensus leaning neutral to bearish. The distribution includes 2 Buy ratings (Canaccord Genuity, B. Riley Securities), 2 Neutral (UBS, Goldman Sachs), and 1 Sell (Citigroup). The average target price is not provided, but the estimated EPS range is -$0.082 to -$0.015, implying continued losses. The consensus recommendation is Neutral, reflecting uncertainty about commercialization. The target range is wide, with the high estimate assuming successful SMR deployment and revenue growth, while the low estimate prices in continued losses and potential dilution. Recent ratings have been stable, with no upgrades or downgrades in the past three months, indicating analysts are waiting for clearer catalysts. The wide spread in estimates suggests high uncertainty, and the limited coverage (5 analysts) is typical for a small-cap, pre-revenue company, leading to higher volatility and less efficient price discovery.
Drowning in data?
Find the real signal!
SMR Technical Analysis
NuScale is in a sustained downtrend, with the stock price falling 72.28% over the past year. The current price of $9.76 sits at 17% of its 52-week range ($8.85 low to $57.42 high), indicating it is near the bottom of the range. This positioning suggests the stock is deeply oversold and potentially a value trap, as the downtrend remains intact without signs of reversal. The 1-month price change of -30.04% shows accelerating downside momentum, while the 3-month change of -3.84% suggests a slight deceleration from the steeper declines earlier in the year. This divergence implies the stock may be attempting to stabilize, but the short-term trend remains bearish. The beta of 2.252 indicates the stock is more than twice as volatile as the S&P 500, amplifying both downside and upside risks. The 52-week low of $8.85 provides a critical support level; a break below could signal further downside, while resistance at the 52-week high of $57.42 is far above. A breakout above resistance would require a fundamental catalyst, but the current trend suggests continued weakness.
Beta
2.25
2.25x market volatility
Max Drawdown
-83.6%
Largest decline past year
52-Week Range
$9-$57
Price range past year
Annual Return
-74.5%
Cumulative gain past year
| Period | SMR Return | S&P 500 |
|---|---|---|
| 1m | -9.7% | +2.0% |
| 3m | -2.0% | +10.6% |
| 6m | -56.0% | +8.3% |
| 1y | -74.5% | +20.4% |
| ytd | -44.6% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SMR Fundamental Analysis
Revenue has collapsed, with the most recent quarter (Q4 2025) reporting only $1.808 million, a 94.72% year-over-year decline from $34.224 million in Q4 2024. The multi-quarter trend shows revenue falling from $13.375 million in Q1 2025 to $1.808 million in Q4 2025, indicating a rapid deceleration. The company is pre-commercial, and its revenue is sporadic, tied to government grants and development milestones. The investment case hinges on future SMR deployments, but the current revenue trajectory is unsustainable. NuScale is deeply unprofitable, with a net loss of $50.829 million in Q4 2025 and a negative gross margin of -3.37%. The net margin was -28.11% in Q4 2025, though this improved from -33.16% in Q3 2025, but the company remains far from profitability. Operating expenses, particularly SG&A of $44.816 million, far exceed revenue, and the company is burning cash rapidly. The balance sheet shows no debt (debt-to-equity of 0) and a current ratio of 4.30, indicating ample liquidity. However, free cash flow was -$204.071 million in Q4 2025, and the company relies on equity financing, having raised $737.882 million from stock issuance in the same quarter. ROE is -30.44%, reflecting significant shareholder dilution and negative returns on equity.
Quarterly Revenue
$1808000.0B
2025-12
Revenue YoY Growth
-94.72%
YoY Comparison
Gross Margin
-3.37%
Latest Quarter
Free Cash Flow
$-460117999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SMR Overvalued?
Since net income is negative, we use the price-to-sales (PS) ratio. The trailing PS ratio is 73.70, while the forward PS ratio is not directly provided but can be inferred from estimated revenue. The extremely high PS ratio reflects minimal revenue relative to market cap, indicating the stock is priced for future growth that has not materialized. Compared to the industry average (data not available), NuScale's PS ratio of 73.70x is astronomically high, even for a pre-revenue growth company. Without industry data, we note that most utilities trade at PS ratios below 5x, so NuScale's multiple is a significant premium, likely unjustified given its revenue decline. Historically, the PS ratio has ranged from 55.48 (Q4 2023) to 1283.23 (Q4 2025), with the current 73.70x near the lower end of its historical band. This suggests the market has de-rated the stock as growth expectations have collapsed, but the valuation remains elevated relative to fundamentals.
PE
-6.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -75x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
